EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital,...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Army Press
2020-12-01
|
Series: | Pakistan Armed Forces Medical Journal |
Subjects: | |
Online Access: | https://pafmj.org/index.php/PAFMJ/article/view/3469 |
id |
doaj-144eb38e17b145c0b5e936fe0bcf2179 |
---|---|
record_format |
Article |
spelling |
doaj-144eb38e17b145c0b5e936fe0bcf21792021-09-10T05:06:29ZengThe Army PressPakistan Armed Forces Medical Journal0030-96482411-88422020-12-0170618851891doi.org/10.51253/pafmj.v70i6.34693469EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTANArif Qayyum Khan0Hala Mansoor1Javed Iqbal Raja2Raja Yasser Shahbaz3Samina Fida4Muhammad Siddique5Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanObjective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.https://pafmj.org/index.php/PAFMJ/article/view/3469hepatitis c virus (hcv)svr 12 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique |
spellingShingle |
Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN Pakistan Armed Forces Medical Journal hepatitis c virus (hcv) svr 12 |
author_facet |
Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique |
author_sort |
Arif Qayyum Khan |
title |
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN |
title_short |
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN |
title_full |
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN |
title_fullStr |
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN |
title_full_unstemmed |
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN |
title_sort |
efficacy of first available direct-acting antiviral agent in treatment of chronic hepatitis c; results from a single centre in pakistan |
publisher |
The Army Press |
series |
Pakistan Armed Forces Medical Journal |
issn |
0030-9648 2411-8842 |
publishDate |
2020-12-01 |
description |
Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C.
Study Design: Comparative cross sectional study.
Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to
Mar 2017.
Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase
chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count
of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were
excluded from study.
Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with
genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with
dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and
100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was
83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia.
Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side
effects, genotype 3 being the most predominant genotype. |
topic |
hepatitis c virus (hcv) svr 12 |
url |
https://pafmj.org/index.php/PAFMJ/article/view/3469 |
work_keys_str_mv |
AT arifqayyumkhan efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT halamansoor efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT javediqbalraja efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT rajayassershahbaz efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT saminafida efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT muhammadsiddique efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan |
_version_ |
1717758577688444928 |